OX1 and OX2 orexin/hypocretin receptor pharmacogenetics

Frontiers in Neuroscience

Volumn , Issue 8 MAY, 2014, Pages

  Thompson, Miles D ^a   Xhaard, Henri ^b   Sakurai, Takeshi ^c   Rainero, Innocenzo ^d   Kukkonen, Jyrki P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KANAZAWA UNIVERSITY   (Japan)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

G protein coupled receptor; Hypocretin; Orexin; Pharmacogenetics; Polymorphism

Indexed keywords

AMINO ACID; G PROTEIN COUPLED RECEPTOR; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN RECEPTOR;

ANXIETY DISORDER; CLUSTER HEADACHE; DAYTIME SOMNOLENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HALF LIFE TIME; HEADACHE; HUMAN; HYPONATREMIA; LIGAND BINDING; MIGRAINE; MOOD DISORDER; NARCOLEPSY; NONHUMAN; PHARMACOGENETICS; POLYDIPSIA; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SLEEP WAKING CYCLE;

EID: 84904891214     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00057     Document Type: Review

References (116)

1. Allard, J. S., Tizabi, Y., Shaffery, J. P., and Manaye, K. (2007). Effects of rapid eye movement sleep deprivation on hypocretin neurons in the hypothalamus of a rat model of depression. Neuropeptides 41, 329-337. doi: 10.1016/j.npep.2007.04.006.
2. Allen, R. P., Singer, H. S., Brown, J. E., and Salam, M. M. (1992). Sleep disorders in Tourette syndrome: a primary or unrelated problem? Pediatr. Neurol. 8, 275-280.
3. Annerbrink, K., Westberg, L., Olsson, M., Andersch, S., Sjodin, I., Holm, G., et al. (2011). Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatr. Genet. 21, 85-89. doi: 10.1097/YPG.0b013e328341a3db.
4. Aston-Jones, G., Smith, R. J., Sartor, G. C., Moorman, D. E., Massi, L., Tahsili-Fahadan, P., et al. (2010). Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res. 1314, 74-90. doi: 10.1016/j.brainres.2009.09.106.
5. Avolio, E., Alo, R., Mele, M., Carelli, A., Canonaco, A., Bucarelli, L., et al. (2012). Amygdalar excitatory/inhibitory circuits interacting with orexinergic neurons influence differentially feeding behaviors in hamsters. Behav. Brain Res. 234, 91-99. doi: 10.1016/j.bbr.2012.06.013.
6. Baumber, L., Sjostrand, C., Leone, M., Harty, H., Bussone, G., Hillert, J., et al. (2006). A genome-wide scan and HCRTR2 candidate gene analysis in a European cluster headache cohort. Neurology 66, 1888-1893. doi: 10.1212/01.wnl.0000219765.95038.d7.
7. Benoliel, R., and Eliav, E. (2013). Primary headache disorders. Dent. Clin. North Am. 57, 513-539. doi: 10.1016/j.cden.2013.04.005.
8. Bingham, S., Davey, P. T., Babbs, A. J., Irving, E. A., Sammons, M. J., Wyles, M., et al. (2001). Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92, 81-90. doi: 10.1016/S0304-3959(00)00470-X.
9. Boutrel, B., Cannella, N., and de Lecea, L. (2010). The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res. 1314, 103-111. doi: 10.1016/j.brainres.2009.11.054.
10. Brundin, L., Bjorkqvist, M., Petersen, A., and Traskman-Bendz, L. (2007). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 17, 573-579. doi: 10.1016/j.euroneuro.2007.01.005.
11. Bulenger, S., Marullo, S., and Bouvier, M. (2005). Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends. Pharmacol. Sci. 26, 131-137. doi: 10.1016/j.tips.2005.01.004.
12. Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451. doi: 10.1016/S0092-8674(00)81973-X.
13. Cohen, A. S., and Goadsby, P. J. (2004). Functional neuroimaging of primary headache disorders. Curr. Neurol. Neurosci. Rep. 4, 105-110. doi: 10.1007/s11910-004-0023-7.
14. Cohrs, S., Rasch, T., Altmeyer, S., Kinkelbur, J., Kostanecka, T., Rothenberger, A., et al. (2001). Decreased sleep quality and increased sleep related movements in patients with Tourette's syndrome. J. Neurol. Neurosurg. Psychiatry 70, 192-197. doi: 10.1136/jnnp.70.2.192.
15. Cox, C. D., Breslin, M. J., Whitman, D. B., Schreier, J. D., McGaughey, G. B., Bogusky, M. J., et al. (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53, 5320-5332. doi: 10.1021/jm100541c.
16. Dalrymple, M. B., Jaeger, W. C., Eidne, K. A., and Pfleger, K. D. (2011). Temporal profiling of orexin receptor-arrestin-ubiquitin complexes reveals differences between receptor subtypes. J. Biol. Chem. 286, 16726-16733. doi: 10.1074/jbc.M111.223537.
17. de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322-327.
18. Deng, B. S., Nakamura, A., Zhang, W., Yanagisawa, M., Fukuda, Y., and Kuwaki, T. (2007). Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. J. Appl. Physiol. 103, 1772-1779. doi: 10.1152/japplphysiol.00075.2007.
19. Diano, S., Horvath, B., Urbanski, H. F., Sotonyi, P., and Horvath, T. L. (2003). Fasting activates the nonhuman primate hypocretin (orexin) system and its postsynaptic targets. Endocrinology 144, 3774-3778. doi: 10.1210/en.2003-0274.
20. Dugovic, C., Shelton, J. E., Aluisio, L. E., Fraser, I. C., Jiang, X., Sutton, S. W., et al. (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 330, 142-151. doi: 10.1124/jpet.109.152009.
21. Duguay, D., Belanger-Nelson, E., Mongrain, V., Beben, A., Khatchadourian, A., and Cermakian, N. (2011). Dynein light chain Tctex-type 1 modulates orexin signaling through its interaction with orexin 1 receptor. PLoS ONE 6:e26430. doi: 10.1371/journal.pone.0026430.
22. El Amrani, M., Ducros, A., Boulan, P., Aidi, S., Crassard, I., Visy, J. M., et al. (2002). Familial cluster headache: a series of 186 index patients. Headache 42, 974-977. doi: 10.1046/j.1526-4610.2002.02226.x.
23. Ellis, J., Pediani, J. D., Canals, M., Milasta, S., and Milligan, G. (2006). Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J. Biol. Chem. 281, 38812-38824. doi: 10.1074/jbc.M602494200.
24. Etori, K., Saito, Y. C., Tsujino, N., and Sakurai, T. (2014). Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front. Neurosci. 8:8. doi: 10.3389/fnins.2014.00008.
25. Feng, P., Vurbic, D., Wu, Z., Hu, Y., and Strohl, K. P. (2008). Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J. Psychopharmacol. 22, 784-791. doi: 10.1177/0269881106082899.
26. Freeman, R. D., Fast, D. K., Burd, L., Kerbeshian, J., Robertson, M. M., and Sandor, P. (2000). An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev. Med. Child Neurol. 42, 436-447. doi: 10.1017/S0012162200000839.
27. Fukunaka, Y., Shinkai, T., Hwang, R., Hori, H., Utsunomiya, K., Sakata, S., et al. (2007). The orexin 1 receptor (HCRTR1) gene as a susceptibility gene contributing to polydipsia-hyponatremia in schizophrenia. Neuromol. Med. 9, 292-297. doi: 10.1007/s12017-007-8001-2.
28. Gencik, M., Dahmen, N., Wieczorek, S., Kasten, M., Bierbrauer, J., Anghelescu, I., et al. (2001). A prepro-orexin gene polymorphism is associated with narcolepsy. Neurology 56, 115-117. doi: 10.1212/WNL.56.1.115.
29. Goadsby, P. J. (2002). Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol. 1, 251-257. doi: 10.1016/S1474-4422(02)00104-7.
30. Hagan, J. J., Leslie, R. A., Patel, S., Evans, M. L., Wattam, T. A., Holmes, S., et al. (1999). Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. U.S.A. 96, 10911-10916. doi: 10.1073/pnas.96.19.10911.
31. Haj-Dahmane, S., and Shen, R. Y. (2005). The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J. Neurosci. 25, 896-905. doi: 10.1523/JNEUROSCI.3258-04.2005.
32. Heifetz, A., Morris, G. B., Biggin, P. C., Barker, O., Fryatt, T., Bentley, J., et al. (2012). Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis. Biochemistry 51, 3178-3197. doi: 10.1021/bi300136h.
33. Hettema, J. M., Neale, M. C., and Kendler, K. S. (2001). A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiatry 158, 1568-1578. doi: 10.1176/appi.ajp.158.10.1568.
34. Holmqvist, T., Johansson, L., östman, M., Ammoun, S., Åkerman, K. E., and Kukkonen, J. P. (2005). OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. J. Biol. Chem. 280, 6570-6579. doi: 10.1074/jbc.M407397200.
35. Horvath, T. L., Peyron, C., Diano, S., Ivanov, A., Aston-Jones, G., Kilduff, T. S., et al. (1999). Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J. Comp. Neurol. 415, 145-159.
36. Huang, J., Chen, S., Zhang, J. J., and Huang, X. Y. (2013). Crystal structure of oligomeric beta1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat. Struct. Mol. Biol. 20, 419-425. doi: 10.1038/nsmb.2504.
37. Hungs, M., Fan, J., Lin, L., Lin, X., Maki, R. A., and Mignot, E. (2001). Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res. 11, 531-539. doi: 10.1101/gr.161001.
38. Ito, N., Yabe, T., Gamo, Y., Nagai, T., Oikawa, T., Yamada, H., et al. (2008). I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 157, 720-732. doi: 10.1016/j.neuroscience.2008.09.042.
39. Jaakola, V. P., Prilusky, J., Sussman, J. L., and Goldman, A. (2005). G protein-coupled receptors show unusual patterns of intrinsic unfolding. Protein Eng. Des. Sel. 18, 103-110. doi: 10.1093/protein/gzi004.
40. Jäntti, M. H., Mandrika, I., and Kukkonen, J. P. (2014). Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun. 445, 486-490. doi: 10.1016/j.bbrc.2014.02.026.
41. Jäntti, M. H., Putula, J., Turunen, P. M., Näsman, J., Reijonen, S., and Kukkonen, J. P. (2013). Autocrine endocannabinoid signaling potentiates orexin receptor signaling upon CB1 cannabinoid-OX1 orexin receptor coexpression. Mol. Pharmacol. 83, 621-632. doi: 10.1124/mol.112.080523.
42. Johnson, P. L., Samuels, B. C., Fitz, S. D., Lightman, S. L., Lowry, C. A., and Shekhar, A. (2012). Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia. Neuropsychopharmacology 37, 1911-1922. doi: 10.1038/npp.2012.38.
43. Kajiyama, S., Kawamoto, M., Shiraishi, S., Gaus, S., Matsunaga, A., Suyama, H., et al. (2005). Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res. 1044, 76-86. doi: 10.1016/j.brainres.2005.03.007.
44. Kantor, S., Mochizuki, T., Lops, S. N., Ko, B., Clain, E., Clark, E., et al. (2013). Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep 36, 1129-1138. doi: 10.5665/sleep.2870.
45. Karteris, E., Machado, R. J., Chen, J., Zervou, S., Hillhouse, E. W., and Randeva, H. S. (2005). Food deprivation differentially modulates orexin receptor expression and signalling in the rat hypothalamus and adrenal cortex. Am. J. Physiol. Endocrinol. Metab. 288, E1089-E1100. doi: 10.1152/ajpendo.00351.2004.
46. Karteris, E., Randeva, H. S., Grammatopoulos, D. K., Jaffe, R. B., and Hillhouse, E. W. (2001). Expression and coupling characteristics of the crh and orexin type 2 receptors in human fetal adrenals. J. Clin. Endocrinol. Metab. 86, 4512-4519.
47. Kis, G. K., Molnar, A. H., Daruka, L., Gardi, J., Rakosi, K., Laszlo, F., et al. (2012). The osmotically and histamine-induced enhancement of the plasma vasopressin level is diminished by intracerebroventricularly administered orexin in rats. Pflugers Arch. 463, 531-536. doi: 10.1007/s00424-012-1080-4.
48. Kukkonen, J. P. (2012). Recent progress in orexin/hypocretin physiology and pharmacology. Biomol. Concepts 3, 447-463. doi: 10.1515/bmc-2012-0013.
49. Kukkonen, J. P. (2013). Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am. J. Physiol. Cell Physiol. 304, C2-C32. doi: 10.1152/ajpcell.00227.2012.
50. Kukkonen, J. P., Holmqvist, T., Ammoun, S., and Åkerman, K. E. (2002). Functions of the orexinergic/hypocretinergic system. Am. J. Physiol. Cell. Physiol. 283, C1567-C1591. doi: 10.1152/ajpcell.00055.2002.
51. Kukkonen, J. P., and Leonard, C. S. (2014). Orexin/hypocretin receptor signalling cascades. Br. J. Pharmacol. 171, 294-313. doi: 10.1111/bph.12324.
52. Kunii, K., Yamanaka, A., Nambu, T., Matsuzaki, I., Goto, K., and Sakurai, T. (1999). Orexins/hypocretins regulate drinking behaviour. Brain Res. 842, 256-261. doi: 10.1016/S0006-8993(99)01884-3.
53. Kuwaki, T. (2008). Orexinergic modulation of breathing across vigilance states. Respir. Physiol. Neurobiol. 164, 204-212. doi: 10.1016/j.resp.2008.03.011.
54. Leonard, C. S., and Kukkonen, J. P. (2014). Orexin/hypocretin receptor signalling: a functional perspective. Br. J. Pharmacol. 171, 294-313. doi: 10.1111/bph.12296.
55. Leone, M., Russell, M. B., Rigamonti, A., Attanasio, A., Grazzi, L., D'Amico, D., et al. (2001). Increased familial risk of cluster headache. Neurology 56, 1233-1236. doi: 10.1212/WNL.56.9.1233.
56. Liang, Y., Fotiadis, D., Filipek, S., Saperstein, D. A., Palczewski, K., and Engel, A. (2003). Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem. 278, 21655-21662. doi: 10.1074/jbc.M302536200.
57. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., et al. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376. doi: 10.1016/S0092-8674(00)81965-0.
58. Lin, Y., Matsumura, K., Tsuchihashi, T., Abe, I., and Iida, M. (2002). Chronic central infusion of orexin-A increases arterial pressure in rats. Brain Res. Bull. 57, 619-622. doi: 10.1016/S0361-9230(01)00756-0.
59. Liu, M., Blanco-Centurion, C., Konadhode, R., Begum, S., Pelluru, D., Gerashchenko, D., et al. (2011). Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J. Neurosci. 31, 6028-6040. doi: 10.1523/JNEUROSCI.6069-10.2011.
60. Madsen, O., Willemsen, D., Ursing, B. M., Arnason, U., and de Jong, W. W. (2002). Molecular evolution of the mammalian alpha 2B adrenergic receptor. Mol. Biol. Evol. 19, 2150-2160. doi: 10.1093/oxfordjournals.molbev.a004040.
61. Magga, J., Bart, G., Oker-Blom, C., Kukkonen, J. P., Åkerman, K. E., and Näsman, J. (2006). Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1. Biochem. Pharmacol. 71, 827-836. doi: 10.1016/j.bcp.2005.12.021.
62. Malherbe, P., Roche, O., Marcuz, A., Kratzeisen, C., Wettstein, J. G., and Bissantz, C. (2010). Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 (SB-674042) and OX2 (EMPA) antagonists. Mol. Pharmacol. 78, 81-93. doi: 10.1124/mol.110.064584.
63. May, A., Ashburner, J., Buchel, C., McGonigle, D. J., Friston, K. J., Frackowiak, R. S., et al. (1999). Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat. Med. 5, 836-838. doi: 10.1038/10561.
64. May, A., Bahra, A., Buchel, C., Frackowiak, R. S., and Goadsby, P. J. (1998). Hypothalamic activation in cluster headache attacks. Lancet 352, 275-278. doi: 10.1016/S0140-6736(98)02470-2.
65. Meerabux, J., Iwayama, Y., Sakurai, T., Ohba, H., Toyota, T., Yamada, K., et al. (2005). Association of an orexin 1 receptor 408Val variant with polydipsia-hyponatremia in schizophrenic subjects. Biol. Psychiatry 58, 401-407. doi: 10.1016/j.biopsych.2005.04.015.
66. Meuret, A. E., Rosenfield, D., Wilhelm, F. H., Zhou, E., Conrad, A., Ritz, T., and Roth, W. T. (2011). Do unexpected panic attacks occur spontaneously? Biol. Psychiatry 70, 985-991. doi: 10.1016/j.biopsych.2011.05.027.
67. Mieda, M., and Sakurai, T. (2013). Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 27, 83-90. doi: 10.1007/s40263-012-0036-8.
68. Milasta, S., Evans, N. A., Ormiston, L., Wilson, S., Lefkowitz, R. J., and Milligan, G. (2005). The sustainability of interactions between the orexin-1 receptor and beta-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. Biochem. J. 387, 573-584. doi: 10.1042/BJ20041745.
69. Milella, M. S., Passarelli, F., De Carolis, L., Schepisi, C., Nativio, P., Scaccianoce, S., et al. (2010). Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia. Psychopharmacology 211, 355-366. doi: 10.1007/s00213-010-1909-5.
70. Milligan, G. (2009). G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14. doi: 10.1111/j.1476-5381.2009.00169.x.
71. Mobarakeh, J. I., Takahashi, K., Sakurada, S., Nishino, S., Watanabe, H., Kato, M., et al. (2005). Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain 118, 254-262. doi: 10.1016/j.pain.2005.08.024.
72. Mori, T., Ito, S., Kuwaki, T., Yanagisawa, M., Sakurai, T., and Sawaguchi, T. (2010). Monoaminergic neuronal changes in orexin deficient mice. Neuropharmacology 58, 826-832. doi: 10.1016/j.neuropharm.2009.08.009.
73. Nishino, S., Ripley, B., Overeem, S., Lammers, G. J., and Mignot, E. (2000). Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39-40. doi: 10.1016/S0140-6736(99)05582-8.
74. Obenauer, J. C., Cantley, L. C., and Yaffe, M. B. (2003). Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31, 3635-3641. doi: 10.1093/nar/gkg584.
75. Olafsdottir, B. R., Rye, D. B., Scammell, T. E., Matheson, J. K., Stefansson, K., and Gulcher, J. R. (2001). Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 57, 1896-1899. doi: 10.1212/WNL.57.10.1896.
76. Ono, K., Kai, A., Honda, E., and Inenaga, K. (2008). Hypocretin-1/orexin-A activates subfornical organ neurons of rats. Neuroreport 19, 69-73. doi: 10.1097/WNR.0b013e3282f32d64.
77. Perna, G., Guerriero, G., and Caldirola, D. (2011). Emerging drugs for panic disorder. Expert Opin. Emerg. Drugs 16, 631-645. doi: 10.1517/14728214.2011.628313.
78. Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y., et al. (2000). A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991-997. doi: 10.1038/79690.
79. Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., et al. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015.
80. Pinessi, L., Rainero, I., Rivoiro, C., Rubino, E., and Gallone, S. (2005). Genetics of cluster headache: an update. J. Headache Pain 6, 234-236. doi: 10.1007/s10194-005-0194-x.
81. Putula, J., and Kukkonen, J. P. (2012). Mapping of the binding sites for the OX(1) orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras. Neurosci. Lett. 506, 111-115. doi: 10.1016/j.neulet.2011.10.061.
82. Putula, J., Turunen, P. M., Johansson, L., Näsman, J., Ra, R., Korhonen, L., et al. (2011). Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction. FEBS Lett. 585, 1368-1374. doi: 10.1016/j.febslet.2011.04.020.
83. Rainero, I., Gallone, S., Rubino, E., Ponzo, P., Valfre, W., Binello, E., et al. (2008). Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. Headache 48, 1108-1114. doi: 10.1111/j.1526-4610.2008.01080.x.
84. Rainero, I., Gallone, S., Valfre, W., Ferrero, M., Angilella, G., Rivoiro, C., et al. (2004). A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. Neurology 63, 1286-1288. doi: 10.1212/01.WNL.0000142424.65251.DB.
85. Rainero, I., Ostacoli, L., Rubino, E., Gallone, S., Picci, L. R., Fenoglio, P., et al. (2011a). Association between major mood disorders and the hypocretin receptor 1 gene. J. Affect. Disord. 130, 487-491. doi: 10.1016/j.jad.2010.10.033.
86. Rainero, I., Rubino, E., Gallone, S., Fenoglio, P., Picci, L. R., Giobbe, L., et al. (2011b). Evidence for an association between migraine and the hypocretin receptor 1 gene. J. Headache Pain 12, 193-199. doi: 10.1007/s10194-011-0314-8.
87. Randeva, H. S., Karteris, E., Grammatopoulos, D., and Hillhouse, E. W. (2001). Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J. Clin. Endocrinol. Metab. 86, 4808-4813. doi: 10.1210/jc.86.10.4808.
88. Ritter, S. L., and Hall, R. A. (2009). Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 10, 819-830. doi: 10.1038/nrm2803.
89. Rodgers, R. J., Halford, J. C., Nunes de Souza, R. L., Canto de Souza, A. L., Piper, D. C., Arch, J. R., et al. (2000). Dose-response effects of orexin-A on food intake and the behavioural satiety sequence in rats. Regul. Pept. 96, 71-84. doi: 10.1016/S0167-0115(00)00203-2.
90. Russell, M. B. (2004). Epidemiology and genetics of cluster headache. Lancet Neurol. 3, 279-283. doi: 10.1016/S1474-4422(04)00735-5.
91. Russell, M. B., Andersson, P. G., and Iselius, L. (1996). Cluster headache is an inherited disorder in some families. Headache 36, 608-612.
92. Russell, S. H., Small, C. J., Dakin, C. L., Abbott, C. R., Morgan, D. G., Ghatei, M. A., et al. (2001). The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats. J. Neuroendocrinol. 13, 561-566. doi: 10.1046/j.1365-2826.2001.00672.x.
93. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585. doi: 10.1016/S0092-8674(00)80949-6.
94. Salomon, R. M., Ripley, B., Kennedy, J. S., Johnson, B., Schmidt, D., Zeitzer, J. M., et al. (2003). Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96-104. doi: 10.1016/S0006-3223(02)01740-7.
95. Schürks, M., Kurth, T., Geissler, I., Tessmann, G., Diener, H. C., and Rosskopf, D. (2006). Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. Neurology 66, 1917-1919. doi: 10.1212/01.wnl.0000215852.35329.34.
96. Schürks, M., Kurth, T., Geissler, I., Tessmann, G., Diener, H. C., and Rosskopf, D. (2007a). The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. Cephalalgia 27, 363-367. doi: 10.1111/j.1468-2982.2007.01287.x.
97. Schürks, M., Limmroth, V., Geissler, I., Tessmann, G., Savidou, I., Engelbergs, J., et al. (2007b). Association between migraine and the G1246A polymorphism in the hypocretin receptor 2 gene. Headache 47, 1195-1199. doi: 10.1111/j.1526-4610.2007.00863.x.
98. Takano, S., Kanai, S., Hosoya, H., Ohta, M., Uematsu, H., and Miyasaka, K. (2004). Orexin-A does not stimulate food intake in old rats. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G1182-1187. doi: 10.1152/ajpgi.00218.2004.
99. Thompson, J. L., and Borgland, S. L. (2011). A role for hypocretin/orexin in motivation. Behav. Brain Res. 217, 446-453. doi: 10.1016/j.bbr.2010.09.028.
100. Thompson, M. D., Burnham, W. M., and Cole, D. E. (2005). The G protein-coupled receptors: pharmacogenetics and disease. Crit. Rev. Clin. Lab. Sci. 42, 311-392. doi: 10.1080/10408360591001895.
101. Thompson, M. D., Cole, D. E., and Jose, P. A. (2008a). Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease. Methods Mol. Biol. 448, 77-107. doi: 10.1007/978-1-59745-205-2_6.
102. Thompson, M. D., Comings, D. E., Abu-Ghazalah, R., Jereseh, Y., Lin, L., Wade, J., et al. (2004). Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette's syndrome comorbidity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129, 69-75. doi: 10.1002/ajmg.b.30047.
103. Thompson, M. D., Noble-Topham, S., Percy, M. E., Andrade, D. M., and Ebers, G. C. (2012). Chromosome 1p36 in migraine with aura: association study of the 5HT(1D) locus. Neuroreport 23, 45-48. doi: 10.1097/WNR.0b013e32834e5af3.
104. Thompson, M. D., Percy, M. E., McIntyre Burnham, W., and Cole, D. E. (2008b). G protein-coupled receptors disrupted in human genetic disease. Methods Mol. Biol. 448, 109-137. doi: 10.1007/978-1-59745-205-2_7.
105. Thompson, M. D., Siminovitch, K. A., and Cole, D. E. (2008c). G protein-coupled receptor pharmacogenetics. Methods Mol. Biol. 448, 139-185. doi: 10.1007/978-1-59745-205-2_8.
106. Tran, D. T., Bonaventure, P., Hack, M., Mirzadegan, T., Dvorak, C., Letavic, M., et al. (2011). Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur. J. Pharmacol. 667, 120-128. doi: 10.1016/j.ejphar.2011.05.074.
107. Turunen, P. M., Jäntti, M. H., and Kukkonen, J. P. (2012). OX1 orexin/hypocretin receptor signaling via arachidonic acid and endocannabinoid release. Mol. Pharmacol. 82, 156-167. doi: 10.1124/mol.112.078063.
108. Ward, R. J., Pediani, J. D., and Milligan, G. (2011). Hetero-multimerization of the cannabinoid CB1 receptor and the orexin OX1 receptor generates a unique complex in which both protomers are regulated by orexin A. J. Biol. Chem. 286, 37414-37428. doi: 10.1074/jbc.M111.287649.
109. Wess, J. (1998). Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol. Ther. 80, 231-264. doi: 10.1016/S0163-7258(98)00030-8.
110. Williams, R. H., and Burdakov, D. (2008). Hypothalamic orexins/hypocretins as regulators of breathing. Expert Rev. Mol. Med. 10, e28. doi: 10.1017/S1462399408000823.
111. Winrow, C. J., Gotter, A. L., Cox, C. D., Doran, S. M., Tannenbaum, P. L., Breslin, M. J., et al. (2011). Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J. Neurogenet. 25, 52-61. doi: 10.3109/01677063.2011.566953.
112. Winrow, C. J., and Renger, J. J. (2014). Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br. J. Pharmacol. 171, 283-293. doi: 10.1111/bph.12261.
113. Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., et al. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071. doi: 10.1126/science.1194396.
114. Xu, T. R., Ward, R. J., Pediani, J. D., and Milligan, G. (2011). The orexin OX1 receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands. Biochem. J. 439, 171-183. doi: 10.1042/BJ20110230.
115. Zhang, W., Fukuda, Y., and Kuwaki, T. (2005). Respiratory and cardiovascular actions of orexin-A in mice. Neurosci. Lett. 385, 131-136. doi: 10.1016/j.neulet.2005.05.032.
116. Zheng, H., Patterson, L. M., and Berthoud, H. R. (2005). Orexin-A projections to the caudal medulla and orexin-induced c-Fos expression, food intake, and autonomic function. J. Comp. Neurol. 485, 127-142. doi: 10.1002/cne.20515.